

Vicente Soriano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4609580/publications.pdf>

Version: 2024-02-01

805
papers

32,105
citations

5876

81
h-index

10127

140
g-index

859
all docs

859
docs citations

859
times ranked

18851
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	13.9	1,560
2	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 339-354.	13.9	699
3	Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. <i>Aids</i> , 1999, 13, 1763-1769.	1.0	540
4	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 355-365.	13.9	498
5	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. <i>Lancet, The</i> , 2010, 376, 367-387.	6.3	431
6	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	1.9	385
7	Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	1.9	362
8	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
9	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	6.3	303
10	Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007, 21, 1073-1089.	1.0	295
11	Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1273-1276.	0.5	295
12	Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 128-133.	2.9	291
13	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. <i>Aids</i> , 2002, 16, 813-828.	1.0	280
14	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. <i>PLoS Medicine</i> , 2005, 2, e112.	3.9	262
15	Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009, 23, 689-696.	1.0	250
16	Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1-4.	1.3	249
17	European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. <i>HIV Medicine</i> , 2008, 9, 82-88.	1.0	222
18	Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2009, 48, e108-e116.	2.9	221

#	ARTICLE	IF	CITATIONS
19	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , 2011, 11, 394-407.	4.6	218
20	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.	0.2	215
21	Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 630-639.	13.9	215
22	Hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2004, 18, 2285-2293.	1.0	213
23	Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1467-1471.	0.5	197
24	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	2.9	197
25	Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	2.9	196
26	Care of patients with hepatitis C and HIV co-infection. <i>Aids</i> , 2004, 18, 1-12.	1.0	194
27	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	3.9	188
28	Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591.	2.9	187
29	Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges. <i>Journal of Infectious Diseases</i> , 2006, 194, 904-911.	1.9	185
30	Pegylated IFN- β plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028.	1.0	183
31	Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982.	0.5	183
32	Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1256.	1.0	180
33	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	2.0	179
34	Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315.	1.9	177
35	Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2005, 40, 1358-1361.	2.9	176
36	Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. <i>Aids</i> , 2001, 15, 309-320.	1.0	169

#	ARTICLE	IF	CITATIONS
37	Antiretroviral drugs and liver injury. <i>Aids</i> , 2008, 22, 1-13.	1.0	163
38	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e754-e764.	2.9	160
39	Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999, 15, 1-4.	2.5	158
40	Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676.	1.9	157
41	HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627.	1.3	156
42	Liver toxicity caused by nevirapine. <i>Aids</i> , 2002, 16, 290-291.	1.0	151
43	New Therapies for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 313-320.	2.9	150
44	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	1.0	149
45	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	1.9	145
46	Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. <i>Aids</i> , 2000, 14, 807-812.	1.0	143
47	Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. <i>Clinical Infectious Diseases</i> , 2004, 38, 430-432.	2.9	128
48	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46.	1.0	127
49	Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. <i>Aids</i> , 2011, 25, 399-409.	1.0	126
50	Protease sequences from HIV-1 group M subtypes A??H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. <i>Aids</i> , 2000, 14, 1489-1495.	1.0	125
51	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.	1.0	120
52	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	3.9	119
53	Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus Type I from a single donor. <i>Transplantation</i> , 2003, 75, 102-104.	0.5	116
54	Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295.	2.9	116

#	ARTICLE	IF	CITATIONS
55	Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 766-768.	1.3	115
56	Renal toxicity associated with tenofovir use. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 545-559.	1.0	111
57	Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 383-386.	1.0	109
58	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.	1.0	109
59	Mutations affecting the replication capacity of the hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2006, 13, 427-434.	1.0	109
60	Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine. <i>HIV Clinical Trials</i> , 2003, 4, 115-120.	2.0	106
61	Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3860-3868.	1.8	103
62	Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153.	1.9	102
63	Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. <i>Aids</i> , 2002, 16, 2352-2354.	1.0	101
64	Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. <i>EMBO Journal</i> , 2000, 19, 5752-5761.	3.5	100
65	Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891.	1.8	98
66	Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. <i>Journal of Virology</i> , 1995, 69, 621-632.	1.5	98
67	Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. <i>International Journal of Infectious Diseases</i> , 2020, 97, 290-292.	1.5	97
68	Gastrointestinal Leishmaniasis in Human Immunodeficiency Virus-Infected Patients: Report of Five Cases and Review. <i>Clinical Infectious Diseases</i> , 1994, 19, 48-53.	2.9	96
69	Tenofovir-related nephrotoxicity in HIV-infected patients. <i>Aids</i> , 2004, 18, 960-963.	1.0	96
70	Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.	2.9	96
71	Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008, 15, 165-172.	1.0	94
72	Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. <i>Aids</i> , 2004, 18, 1109-1116.	1.0	93

#	ARTICLE	IF	CITATIONS
73	Main differences between the first and second waves of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 105, 374-376.	1.5	92
74	Hepatotoxicity of Antiretrovirals. <i>Drug Safety</i> , 2005, 28, 53-66.	1.4	91
75	Management of chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 1999, 13, 539-546.	1.0	90
76	Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. , 2000, 61, 111-116.		89
77	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. <i>Antiviral Therapy</i> , 2011, 16, 339-348.	0.6	89
78	Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2008, 15, 427-433.	1.0	87
79	Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 699-704.	1.3	87
80	Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1549-1553.	2.9	85
81	Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , 2010, 24, 1171-1176.	1.0	84
82	Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.	1.3	81
83	Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1370-1374.	1.8	81
84	CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 227-233.	0.5	80
85	Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 709-713.	1.3	79
86	Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.	1.0	79
87	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.	1.4	78
88	Management of chronic hepatitis B and C in HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 815-818.	1.3	78
89	Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1174-1180.	1.3	78
90	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	1.3	76

#	ARTICLE	IF	CITATIONS
91	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	1.0	75
92	Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. <i>Aids</i> , 2000, 14, 2153-2157.	1.0	74
93	Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. <i>Aids</i> , 2011, 25, 73-79.	1.0	74
94	Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007, 22, 2353-2358.	0.4	72
95	Lack of "occult" hepatitis B virus infection in HIV-infected patients. <i>Aids</i> , 2002, 16, 2099-2101.	1.0	72
96	HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367.	1.0	71
97	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205.	1.3	70
98	Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, 11-16.	1.0	67
99	Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 201-205.	2.0	66
100	Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 679-688.	0.9	66
101	Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1031-1036.	1.8	66
102	Population Pharmacokinetic Modeling of the Association between 63396C>T Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	1.4	66
103	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47.	0.5	66
104	Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. <i>British Journal of Haematology</i> , 1997, 98, 927-933.	1.2	65
105	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17.	1.0	65
106	Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. <i>Journal of Medical Virology</i> , 2004, 74, 21-28.	2.5	64
107	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146.	1.0	64
108	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , 2006, 20, 1951-1954.	1.0	64

#	ARTICLE	IF	CITATIONS
109	Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1365-1373.	1.3	64
110	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010.	1.3	64
111	Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. <i>Aids</i> , 2012, 26, 1387-1392.	1.0	64
112	Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015.	1.5	64
113	Management of patients co-infected with hepatitis B virus and HIV. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 374-382.	4.6	63
114	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1486-1492.	1.3	63
115	Introduction of HIV drug-resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1007-1014.	1.0	62
116	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.	0.2	62
117	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	1.4	62
118	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.	1.0	62
119	Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999, 31, 119-123.	1.8	61
120	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001, 15, 1701-1706.	1.0	61
121	High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. <i>Aids</i> , 2002, 16, 1163-1170.	1.0	61
122	Hepatitis C viraemia in HIV/HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 212.	1.0	61
123	Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate. <i>Virology</i> , 1997, 236, 364-373.	1.1	60
124	Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. <i>Clinical Immunology</i> , 2011, 139, 110-114.	1.4	60
125	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	1.7	60
126	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179.	1.0	60

#	ARTICLE	IF	CITATIONS
127	Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 275-278.	0.5	59
128	Frequent hepatitis B virus rebound among HIV-1 hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	1.0	59
129	SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. <i>HIV Clinical Trials</i> , 2002, 3, 186-194.	2.0	58
130	Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain. <i>Current HIV Research</i> , 2008, 6, 327-334.	0.2	58
131	Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. <i>Aids</i> , 2002, 16, 245-249.	1.0	57
132	Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21.	1.0	57
133	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170.	0.9	57
134	Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-1 positive patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 47-52.	1.0	57
135	Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future. <i>Clinical Infectious Diseases</i> , 2003, 37, 1678-1685.	2.9	56
136	Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. <i>Journal of Clinical Virology</i> , 2004, 31, 215-220.	1.6	56
137	Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2918-2923.	1.8	56
138	Pharmacogenetics of tenofovir treatment. <i>Pharmacogenomics</i> , 2009, 10, 1675-1685.	0.6	56
139	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	2.9	56
140	Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. <i>Aids</i> , 2014, 28, 2389-2394.	1.0	56
141	Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. <i>Journal of Clinical Virology</i> , 2005, 34, 295-301.	1.6	55
142	Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. <i>Journal of Clinical Virology</i> , 2006, 36, 264-271.	1.6	55
143	Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006, 6, 234-245.	0.9	55
144	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	1.9	55

#	ARTICLE	IF	CITATIONS
145	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013, 27, 81-85.	1.0	55
146	Comparative Performance of Three Viral Load Assays on Human Immunodeficiency Virus Type 1 (HIV-1) Isolates Representing Group M (Subtypes A to G) and Group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR Version 1.5, and Quantiplex HIV-1 RNA Version 3.0. <i>Journal of Clinical Microbiology</i> , 2001, 39, 862-870.	1.8	54
147	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.	1.3	54
148	Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 320-326.	1.3	54
149	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. <i>Aids</i> , 2000, 14, 727-732.	1.0	53
150	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.	2.9	53
151	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 694-698.	1.3	53
152	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	2.9	53
153	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.	1.0	53
154	Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1215-1223.	0.9	53
155	Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. <i>Journal of Hepatology</i> , 1998, 28, 526-527.	1.8	52
156	Are Fusion Inhibitors Active against All HIV Variants?. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 347-348.	0.5	51
157	Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039.	2.9	51
158	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	1.3	51
159	Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 543-547.	1.3	51
160	Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. <i>Aids</i> , 2002, 16, 1959-1961.	1.0	51
161	Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767.	2.5	50
162	Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. <i>Antiviral Therapy</i> , 2017, 22, 307-312.	0.6	50

#	ARTICLE	IF	CITATIONS
163	Evaluation of performance across the dynamic range of the Abbott RealTime [®] HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. <i>Journal of Virological Methods</i> , 2007, 141, 49-57.	1.0	49
164	Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009, 16, 895-896.	1.0	49
165	Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. <i>Aids</i> , 2005, 19, 221-40.	1.0	49
166	CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. <i>Aids</i> , 1994, 8, 1621.	1.0	48
167	Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. <i>Journal of Infectious Diseases</i> , 1998, 177, 227-231.	1.9	48
168	The effect of antiretroviral therapy on HTLV infection. <i>Virus Research</i> , 2001, 78, 93-100.	1.1	48
169	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011, 90, 164-167.	1.9	48
170	Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.	1.1	48
171	Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. <i>Aids</i> , 2002, 16, 2079-2081.	1.0	48
172	Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. <i>Journal of Medical Virology</i> , 2004, 74, 521-527.	2.5	47
173	Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy. <i>Aids</i> , 2008, 22, 1779-1787.	1.0	47
174	Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 923-932.	1.0	47
175	HIV-1 Causing AIDS and Death in a Seronegative Individual. <i>Vox Sanguinis</i> , 1994, 67, 410-411.	0.7	46
176	Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 33, 1793-1795.	2.9	46
177	HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. <i>HIV Medicine</i> , 2005, 6, 313-320.	1.0	46
178	Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , 2005, 19, 2036-2038.	1.0	46
179	Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009, 155, 35-43.	1.1	46
180	Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. <i>HIV Medicine</i> , 2013, 14, 614-623.	1.0	46

#	ARTICLE	IF	CITATIONS
181	Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 333-341.	1.5	46
182	Efficacy and safety of \pm -interferon treatment for chronic hepatitis C in HIV-infected patients. Journal of Infection, 1995, 31, 9-13.	1.7	45
183	Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver International, 2013, 33, 1357-1362.	1.9	45
184	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981.	1.1	45
185	Impact of Chronic Hepatitis C on HIV-1 Disease Progression. HIV Clinical Trials, 2004, 5, 125-131.	2.0	44
186	Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2004, 20, 698-700.	0.5	44
187	Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. Antiviral Therapy, 2012, 17, 921-926.	0.6	44
188	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. Journal of Medical Virology, 2007, 79, 1040-1046.	2.5	43
189	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids, 2008, 22, 367-376.	1.0	43
190	New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2017, 26, 843-851.	1.9	43
191	Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2004, 20, 351-353.	0.5	42
192	Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. Journal of Virological Methods, 2005, 127, 54-59.	1.0	42
193	Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrobial Agents and Chemotherapy, 2005, 49, 3997-4008.	1.4	42
194	Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. Journal of Infectious Diseases, 2007, 195, 1181-1183.	1.9	42
195	Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. Aids, 2007, 21, 1487-1490.	1.0	42
196	Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. International Journal of Antimicrobial Agents, 2002, 20, 438-443.	1.1	41
197	Changes in Mitochondrial DNA Copy Number in Blood Cells from HIV-Infected Patients Undergoing Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 271-273.	0.5	41
198	Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs, 2008, 13, 1-19.	1.0	41

#	ARTICLE	IF	CITATIONS
199	Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227.	0.5	41
200	Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group. <i>Clinical Infectious Diseases</i> , 2011, 52, 1257-1266.	2.9	41
201	Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 569-572.	1.8	41
202	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220.	1.8	41
203	Hepatitis C virus resistance to the new direct-acting antivirals. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1197-1209.	1.5	41
204	Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families. <i>HIV Clinical Trials</i> , 2002, 3, 304-309.	2.0	40
205	Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. <i>Journal of Hepatology</i> , 2008, 49, 323-328.	1.8	40
206	Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1493-1496.	1.3	40
207	HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. <i>Aids</i> , 2004, 18, 495-502.	1.0	39
208	Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825.	0.5	39
209	Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822.	1.3	39
210	Antiviral effect of raltegravir on HTLV-1 carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 218-221.	1.3	39
211	Cryptosporidiosis. <i>New England Journal of Medicine</i> , 2002, 347, 1287-1287.	13.9	38
212	HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629.	0.9	38
213	Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 185, 982-989.	0.4	38
214	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	1.3	38
215	Third wave of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 107, 212-214.	1.5	38
216	The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013, 15, 25-31.	0.5	38

#	ARTICLE	IF	CITATIONS
217	Prevalence of HTLV infection in pregnant women in Spain. <i>Sexually Transmitted Infections</i> , 2000, 76, 366-370.	0.8	37
218	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , 2008, 22, 611-616.	1.0	37
219	Natural Polymorphisms Associated with Resistance to New Antivirals against HCV in Newly Diagnosed HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2011, 16, 413-416.	0.6	37
220	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016, 17, 590-600.	1.0	37
221	Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. <i>Aids</i> , 2001, 15, 1894-1896.	1.0	37
222	Predictors of selection of K65R. <i>Aids</i> , 2004, 18, 2094-2096.	1.0	36
223	Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2006, 43, 1209-1212.	2.9	36
224	Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2008, 47, 94-101.	2.9	36
225	Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008, 22, 2535-2537.	1.0	36
226	Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 457-477.	1.5	36
227	HTLV-I/II Infections in Spain. <i>International Journal of Epidemiology</i> , 1993, 22, 716-719.	0.9	35
228	Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 879-885.	0.5	35
229	Telbivudine: a new option for the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 751-761.	1.4	35
230	Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. <i>Aids</i> , 2007, 21, 2521-2527.	1.0	35
231	Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 387-391.	1.0	35
232	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.	2.9	35
233	Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 790-795.	1.0	35
234	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 881-886.	0.6	35

#	ARTICLE	IF	CITATIONS
235	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028.	1.3	35
236	Hepatitis delta and HIV infection. <i>Aids</i> , 2017, 31, 875-884.	1.0	35
237	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	1.1	35
238	First Case of HIV-1 Group O Infection in Spain. <i>Vox Sanguinis</i> , 1996, 71, 66-66.	0.7	34
239	Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. <i>Journal of Viral Hepatitis</i> , 2000, 7, 403-408.	1.0	34
240	Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. <i>Virus Research</i> , 2000, 66, 13-26.	1.1	34
241	Prevalence of Human Immunodeficiency Virus Type 1 (HIV-1) Non-B Subtypes in Foreigners Living in Madrid, Spain, and Comparison of the Performances of the AMPLICOR HIV-1 MONITOR Version 1.0 and the New Automated Version 1.5. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1850-1854.	1.8	34
242	Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nucleoside Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1379-1388.	0.5	34
243	Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 657-659.	0.5	34
244	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010, 24, 467-469.	1.0	34
245	Noncirrhotic portal hypertension in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 12-18.	1.3	34
246	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfecting patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.	1.8	34
247	Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. <i>AIDS Reviews</i> , 2012, 14, 223-30.	0.5	34
248	Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1245-1247.	1.8	33
249	Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , 2006, 78, 1599-1608.	2.5	33
250	Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 806-809.	1.3	33
251	Optimal use of maraviroc in clinical practice. <i>Aids</i> , 2008, 22, 2231-2240.	1.0	33
252	When and how to use maraviroc in HIV-infected patients. <i>Aids</i> , 2009, 23, 2377-2385.	1.0	33

#	ARTICLE	IF	CITATIONS
253	Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1567-1569.	1.3	33
254	Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208.	1.0	33
255	Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	1.9	33
256	Genetic mechanisms of resistance to NRTI and NNRTI. <i>HIV Clinical Trials</i> , 2002, 3, 237-248.	2.0	32
257	Resistance to Antiretroviral Agents in Individuals with HIV-1 Non-B Subtypes. <i>HIV Clinical Trials</i> , 2002, 3, 403-411.	2.0	32
258	Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1026-1031.	0.5	32
259	Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. <i>Clinical Infectious Diseases</i> , 2004, 39, 1231-1238.	2.9	32
260	Clinical benefit of interventions driven by therapeutic drug monitoring. <i>HIV Medicine</i> , 2005, 6, 360-365.	1.0	32
261	Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 537-542.	2.0	32
262	Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. <i>European Journal of Immunology</i> , 2007, 37, 501-515.	1.6	32
263	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007, 54, 173-179.	1.7	32
264	Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753.	1.0	32
265	Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 139-144.	1.9	32
266	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	1.1	32
267	Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. <i>Journal of Medical Virology</i> , 2000, 61, 111-6.	2.5	32
268	Evidence of Nef Truncation in Human Immunodeficiency Virus Type 2 Infection. <i>Journal of Infectious Diseases</i> , 1998, 177, 65-71.	1.9	31
269	Short Communication: Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 187-188.	0.5	31
270	First-Line Therapy and Mitochondrial Damage: Different Nucleosides, Different Findings. <i>HIV Clinical Trials</i> , 2003, 4, 11-19.	2.0	31

#	ARTICLE	IF	CITATIONS
271	Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.	2.9	31
272	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1409-1410.	1.3	31
273	Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 325-330.	1.0	31
274	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	1.9	31
275	Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 739-748.	0.8	31
276	Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. <i>Aids</i> , 2002, 16, 1423-1425.	1.0	31
277	Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. <i>Aids</i> , 2002, 16, 1964-1966.	1.0	31
278	Protease Gene Analysis of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1395-1403.	0.5	30
279	Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3865-3866.	1.8	30
280	Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2007, 7, 382-390.	1.0	30
281	Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. <i>Aids</i> , 2008, 22, 2395-2398.	1.0	30
282	Seroprevalence of HTLV-1/2 Infection among Native and Immigrant Pregnant Women in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 551-554.	0.5	30
283	Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. <i>Journal of Clinical Virology</i> , 2009, 46, 173-175.	1.6	30
284	Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). <i>HIV Medicine</i> , 2011, 12, 374-382.	1.0	30
285	Inpatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.	1.0	30
286	Pharmacogenetics of hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 523-529.	1.3	30
287	Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323.	0.9	30
288	Dolutegravir for the treatment of HIV-2 infection. <i>Journal of Clinical Virology</i> , 2015, 64, 12-15.	1.6	30

#	ARTICLE	IF	CITATIONS
289	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017, 31, 1653-1663.	1.0	30
290	Recombinant Human Immunodeficiency Viruses Type 1 Circulating in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 505-511.	0.5	29
291	Natural history of Hymenoptera venom allergy in Eastern Spain. <i>Clinical and Experimental Allergy</i> , 2005, 35, 179-185.	1.4	29
292	HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates. <i>Journal of Clinical Virology</i> , 2006, 35, 244-249.	1.6	29
293	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006, 20, 1071-1074.	1.0	29
294	Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 679-683.	0.5	29
295	An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI E V 2E Quality Control Study. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3491-3497.	1.8	29
296	Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1484-1488.	1.3	29
297	Resistance to HIV Protease Inhibitors: Mechanisms and Clinical Consequences. <i>Current Drug Metabolism</i> , 2004, 5, 321-328.	0.7	29
298	Opportunistic Infections Shortly after Beginning Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 1998, 3, 229-231.	0.6	29
299	Management of hepatitis C in HIV-infected persons. <i>Antiviral Research</i> , 2001, 52, 189-198.	1.9	28
300	Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1518-1521.	1.8	28
301	Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity. <i>HIV Clinical Trials</i> , 2005, 6, 197-202.	2.0	28
302	Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 802-806.	1.0	28
303	Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59.	1.0	28
304	A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 264-270.	1.4	28
305	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20.	1.1	27
306	Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. <i>Journal of Medical Virology</i> , 2005, 76, 268-270.	2.5	27

#	ARTICLE	IF	CITATIONS
307	Impact of IL28B gene polymorphisms on interferon- α 3 plasma levels during pegylated interferon- α /ribavirin therapy for chronic hepatitis C in patients coinfecting with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1246-1249.	1.3	27
308	Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1117-1122.	2.9	27
309	Hepatitis B, C, and D and HIV Infections among Immigrants from Equatorial Guinea Living in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 789-794.	0.6	27
310	Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2083-2088.	1.3	27
311	Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. <i>Clinical and Diagnostic Virology</i> , 1996, 7, 85-92.	1.8	26
312	Performance of Six Different Ritonavir-Boosted Protease Inhibitor-Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2006, 7, 163-171.	2.0	26
313	Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. <i>HIV Clinical Trials</i> , 2006, 7, 246-250.	2.0	26
314	Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1374-1376.	0.5	26
315	Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007, 79, 503-510.	2.5	26
316	Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 157-165.	0.5	26
317	Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. <i>Aids</i> , 2011, 25, 269-271.	1.0	26
318	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.	1.0	26
319	Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096502.	1.1	26
320	Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. <i>Aids</i> , 1999, 13, 524.	1.0	26
321	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. <i>Aids</i> , 2002, 16, 1830-1832.	1.0	26
322	Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. <i>Journal of Infection</i> , 1994, 28, 255-259.	1.7	25
323	Naturally Occurring Sequence Polymorphisms within HIV Type 1 Group O Protease. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1555-1561.	0.5	25
324	Hcv Chronic Hepatitis in Patients With Hiv: Clinical Management Issues. <i>American Journal of Gastroenterology</i> , 2002, 97, 1598-1606.	0.2	25

#	ARTICLE	IF	CITATIONS
325	Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon $\hat{\pm}$ -2b Plus Ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1083-1089.	0.5	25
326	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118.	1.0	25
327	Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1171-1181.	1.9	25
328	Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. <i>Clinical Infectious Diseases</i> , 2012, 55, e1-e4.	2.9	25
329	Management and Treatment of Chronic Hepatitis C in HIV Patients. <i>Seminars in Liver Disease</i> , 2012, 32, 138-146.	1.8	25
330	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	1.1	25
331	Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. <i>Aids</i> , 1999, 13, 525.	1.0	25
332	Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000, 14, 1672-1673.	1.0	25
333	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.	1.0	24
334	Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1). <i>Journal of Clinical Microbiology</i> , 2007, 45, 88-92.	1.8	24
335	Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410.	1.3	24
336	Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. <i>Journal of Clinical Virology</i> , 2007, 38, 176-180.	1.6	24
337	Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008, 15, 363-369.	1.0	24
338	HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , 2011, 52, 119-122.	1.6	24
339	Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.	1.0	24
340	The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.	1.9	24
341	Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134.	1.0	24
342	IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014, 9, e95515.	1.1	24

#	ARTICLE	IF	CITATIONS
343	Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014, 28, 1473-1478.	1.0	24
344	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7.	1.9	24
345	Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 309-315.	1.5	24
346	Emerging viral infections—a potential threat for blood supply in the 21st century. <i>AIDS Reviews</i> , 2012, 14, 279-89.	0.5	24
347	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. <i>HIV Clinical Trials</i> , 2002, 3, 99-114.	2.0	23
348	Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center. <i>HIV Clinical Trials</i> , 2005, 6, 329-336.	2.0	23
349	Heterogeneous nature of HIV-1 recombinants spreading in Spain. <i>Journal of Medical Virology</i> , 2005, 75, 374-380.	2.5	23
350	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 23-28.	2.5	23
351	Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. <i>Aids</i> , 2006, 20, 1460-1462.	1.0	23
352	Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649.	1.4	23
353	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 rd Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3729-3742.	1.4	23
354	Antiretroviral drug-related toxicities — clinical spectrum, prevention, and management. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 697-707.	1.0	23
355	Emerging Challenges in Managing Hepatitis B in HIV Patients. <i>Current HIV/AIDS Reports</i> , 2015, 12, 344-352.	1.1	23
356	Treatment of hepatitis C with new fixed dose combinations. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1235-1242.	0.9	23
357	Chemokine receptors and HIV-2. <i>Aids</i> , 1997, 11, 1198-1199.	1.0	22
358	Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. <i>Journal of Hepatology</i> , 2006, 44, S44-S48.	1.8	22
359	Reliability of Rapid Subtyping Tools Compared to That of Phylogenetic Analysis for Characterization of Human Immunodeficiency Virus Type 1 Non-B Subtypes and Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3896-3899.	1.8	22
360	Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 1187-1188.	1.0	22

#	ARTICLE	IF	CITATIONS
361	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	1.3	22
362	New hepatitis C therapies for special patient populations. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 217-229.	0.9	22
363	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. <i>PLoS ONE</i> , 2016, 11, e0155245.	1.1	22
364	Seroreversion in Patients with End-stage HIV Infection. <i>Vox Sanguinis</i> , 1994, 67, 238-239.	0.7	21
365	Sequence Note:envGene Characterization of the First HIV Type 1 Group O Spanish Isolate. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1647-1649.	0.5	21
366	Molecular Evidence of Homosexual Transmission of HIV Type 2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 417-422.	0.5	21
367	Avascular Necrosis in HIV-Infected Patients Receiving Antiretroviral Treatment: Study of Seven Cases. <i>HIV Clinical Trials</i> , 2003, 4, 132-136.	2.0	21
368	Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 460-464.	2.5	21
369	Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. <i>Epidemiology and Infection</i> , 2007, 135, 592-603.	1.0	21
370	Elevated TGF- β 1 levels might protect HCV/HIV-1 coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011, 41, 70-76.	1.7	21
371	Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. <i>Journal of Neurology</i> , 2013, 260, 2551-2555.	1.8	21
372	Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. <i>International Journal of Infectious Diseases</i> , 2021, 112, 81-88.	1.5	21
373	The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. <i>Journal of Infection</i> , 1998, 36, 307-311.	1.7	20
374	Regression of Invasive AIDS-Related Kaposi's Sarcoma Following Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1998, 26, 218-219.	2.9	20
375	Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. <i>Aids</i> , 2000, 14, 913-919.	1.0	20
376	Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. <i>Sexually Transmitted Infections</i> , 2002, 78, 255-260.	0.8	20
377	CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation. <i>Journal of Infectious Diseases</i> , 2005, 192, 2142-2146.	1.9	20
378	Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. <i>Aids</i> , 2006, 20, 1558-1560.	1.0	20

#	ARTICLE	IF	CITATIONS
379	Liver Fibrosis Stage and HCV Genotype Distribution in HIV/HCV Coinfected Patients with Persistently Normal Transaminases. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 801-804.	0.5	20
380	Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. <i>HIV Clinical Trials</i> , 2007, 8, 98-101.	2.0	20
381	Introduction of Non-B Subtypes among Spaniards Newly Diagnosed with HIV Type 1 in the Canary Islands. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 498-502.	0.5	20
382	Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 935-940.	0.5	20
383	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/Hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133.	1.0	20
384	Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. <i>Clinical Infectious Diseases</i> , 2013, 56, 560-566.	2.9	20
385	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. <i>Journal of Translational Medicine</i> , 2016, 14, 257.	1.8	20
386	Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1060-1062.	0.8	20
387	HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 706.	1.3	20
388	Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz070.	0.4	20
389	Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020, 34, 1019-1027.	1.0	20
390	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	1.9	20
391	Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 857-860.	0.5	19
392	Viral Response to Antiretroviral Therapy in a Patient Coinfected with HIV Type 1 and Type 2. <i>Clinical Infectious Diseases</i> , 2005, 41, e19-e21.	2.9	19
393	Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 839-850.	0.9	19
394	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1782-1785.	2.9	19
395	Injecting, Sexual Risk Behaviors and HIV Infection in Young Cocaine and Heroin Users in Spain. <i>European Addiction Research</i> , 2009, 15, 171-178.	1.3	19
396	European guideline for the management of hepatitis B and C virus infections, 2010. <i>International Journal of STD and AIDS</i> , 2010, 21, 669-678.	0.5	19

#	ARTICLE	IF	CITATIONS
397	Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2502-2504.	1.3	19
398	Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. <i>Journal of Infection</i> , 2011, 63, 382-390.	1.7	19
399	Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2838-2842.	1.3	19
400	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	1.9	19
401	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. <i>PLoS ONE</i> , 2014, 9, e116226.	1.1	19
402	Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 211-219.	0.9	19
403	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015, 29, 1895-1897.	1.0	19
404	Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1735-1738.	1.8	19
405	False positives for HIV using commercial viral load quantification assays. <i>Aids</i> , 1998, 12, 2076-2077.	1.0	18
406	Human immunodeficiency viruses type 1 subtypes circulating in Spain. <i>Journal of Medical Virology</i> , 1999, 59, 189-193.	2.5	18
407	Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. <i>HIV Clinical Trials</i> , 2002, 3, 9-16.	2.0	18
408	Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 154-159.	0.9	18
409	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 626-627.	1.3	18
410	HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. <i>Antiviral Therapy</i> , 2011, 16, 585-589.	0.6	18
411	High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3380-3382.	1.8	18
412	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.	0.5	18
413	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527.	1.8	18
414	Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Child-Pugh B Compensated Cirrhosis. <i>Antiviral Therapy</i> , 2016, 21, 91-92.	0.6	18

#	ARTICLE	IF	CITATIONS
415	Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421.	1.9	18
416	HIV type 2 epidemic in Spain. <i>Aids</i> , 2017, 31, 1353-1364.	1.0	18
417	Replacing stavudine by abacavir reduces lactate levels and may improve lipotrophy. <i>Aids</i> , 2003, 17, 921-924.	1.0	18
418	Report from the International Conference on Viral Hepatitis (ICVH) – Chicago, October 2017. <i>AIDS Reviews</i> , 2018, 20, .	0.5	18
419	High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. <i>Journal of Infection</i> , 1994, 28, 100-102.	1.7	17
420	Human Immunodeficiency Virus Type 2 Infection in Spain. <i>Intervirology</i> , 1999, 42, 37-42.	1.2	17
421	Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. <i>Journal of Medical Virology</i> , 2001, 63, 85-87.	2.5	17
422	Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, e118-e120.	2.9	17
423	Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. <i>Virus Genes</i> , 2007, 34, 111-116.	0.7	17
424	Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools. <i>Journal of Medical Virology</i> , 2008, 80, 383-391.	2.5	17
425	Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1470-1472.	1.3	17
426	Editorial Commentary: Risks and Benefits of Using Antiretroviral Therapy in HIV-Infected Patients with Chronic Hepatitis B in Developing Regions. <i>Clinical Infectious Diseases</i> , 2008, 47, 1486-1489.	2.9	17
427	Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 333-340.	0.5	17
428	Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 656-659.	0.5	17
429	IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus/HCV coinfected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 358-366.	1.0	17
430	Faldaprevir and pegylated interferon \pm -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.	1.0	17
431	Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1421-1434.	1.0	17
432	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17

#	ARTICLE	IF	CITATIONS
433	Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. <i>Clinical Microbiology and Infection</i> , 2001, 7, 678-681.	2.8	16
434	HIV-Positive Immigrants in the Canary Islands, Spain: Implications for Public Health in Europe. <i>HIV Clinical Trials</i> , 2003, 4, 184-192.	2.0	16
435	Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2003, 4, 361-371.	2.0	16
436	Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , 2004, 18, 2091-2094.	1.0	16
437	Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 44, 105-110.	2.9	16
438	Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 891-894.	0.5	16
439	Prevalence of and Risk Factors for Hepatitis B Virus Infection among Street-Recruited Young Injection and Non-Injection Heroin Users in Barcelona, Madrid and Seville. <i>European Addiction Research</i> , 2008, 14, 116-124.	1.3	16
440	Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005-2007). <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 37-44.	0.5	16
441	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	0.6	16
442	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011, 12, 487-493.	1.0	16
443	Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295.	2.9	16
444	Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. <i>European Journal of Immunology</i> , 2013, 43, 499-509.	1.6	16
445	Stability of hepatitis C virus (HCV) RNA levels among interferon- α -ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 370-378.	1.0	16
446	Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 475-479.	1.0	16
447	Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2015, 20, 329-334.	0.6	16
448	Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72.	0.6	16
449	Hypoglycemia in a diabetic patient during hepatitis C therapy. <i>Hepatology</i> , 2016, 63, 2065-2066.	3.6	16
450	Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain. <i>Antiviral Therapy</i> , 2018, 23, 87-90.	0.6	16

#	ARTICLE	IF	CITATIONS
451	Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 807-816.	1.5	16
452	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. Journal of Antimicrobial Chemotherapy, 2019, 74, 1357-1362.	1.3	16
453	Long-acting antiretroviral therapy. Nature Materials, 2020, 19, 826-827.	13.3	16
454	Why such excess of mortality for COVID-19 in Spain?. Therapeutic Advances in Infectious Disease, 2020, 7, 204993612093275.	1.1	16
455	High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. Journal of Hepatology, 1995, 22, 598-599.	1.8	15
456	A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. Journal of Infection, 1997, 35, 225-230.	1.7	15
457	New paradigms in the management of HIV and hepatitis C virus coinfection. Current Opinion in Infectious Diseases, 2005, 18, 550-560.	1.3	15
458	Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin. HIV Clinical Trials, 2005, 6, 278-280.	2.0	15
459	Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. Journal of Clinical Virology, 2005, 33, 65-70.	1.6	15
460	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. Clinical and Translational Oncology, 2006, 8, 193-199.	1.2	15
461	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. Scandinavian Journal of Infectious Diseases, 2006, 38, 1092-1097.	1.5	15
462	Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. Journal of Viral Hepatitis, 2007, 14, 392-395.	1.0	15
463	Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Journal of Viral Hepatitis, 2008, 15, 710-715.	1.0	15
464	Prevalence of HTLV-1/2 Infections in Spain: A Cross-Sectional Hospital-Based Survey. AIDS Research and Human Retroviruses, 2010, 26, 861-864.	0.5	15
465	Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 641-644.	1.3	15
466	Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research, 2013, 100, 435-438.	1.9	15
467	HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfecting patients on hepatitis C virus therapy. Aids, 2013, 27, 1231-1238.	1.0	15
468	Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. Aids, 2013, 27, 2219-2224.	1.0	15

#	ARTICLE	IF	CITATIONS
469	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.	1.0	15
470	Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 5-16.	1.5	15
471	Characterization of Free Phenytoin Concentrations in End-Stage Renal Disease Using the Winter-Tozer Equation. <i>Annals of Pharmacotherapy</i> , 2017, 51, 669-674.	0.9	15
472	Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS. <i>AIDS Reviews</i> , 2019, 20, 187-204.	0.5	15
473	Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. <i>Clinical Infectious Diseases</i> , 2021, 72, 1101-1102.	2.9	15
474	Spanish consensus conference on drug resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1998.	1.0	15
475	Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <i>Aids</i> , 2002, 16, 493-495.	1.0	15
476	Genetic mechanisms of resistance to NRTI and NNRTI. <i>HIV Clinical Trials</i> , 2002, 3, 237-48.	2.0	15
477	Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. <i>Journal of Virological Methods</i> , 1994, 49, 37-46.	1.0	14
478	Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 363-368.	0.5	14
479	Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2008, 38, 1548-1558.	1.6	14
480	Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 967-972.	0.5	14
481	Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 633-638.	0.5	14
482	Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1007-1014.	0.9	14
483	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.	1.0	14
484	Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2616-2625.	1.3	14
485	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014, 28, 1603-1609.	1.0	14
486	HIV co-infection in HTLV-1 carriers in Spain. <i>Virus Research</i> , 2019, 266, 48-51.	1.1	14

#	ARTICLE	IF	CITATIONS
487	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972.	1.9	14
488	Sequencing antiretroviral drugs. <i>Aids</i> , 2001, 15, 547-551.	1.0	13
489	Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 457-459.	0.5	13
490	Management of Chronic Hepatitis C in Patients Co-Infected with HIV. <i>Drug Safety</i> , 2004, 27, 7-24.	1.4	13
491	Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006, 13, 851-857.	1.0	13
492	Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1237-1241.	0.5	13
493	Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1067-1074.	0.5	13
494	Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "ask, draw a blood sample, vaccinate and try to schedule another visit". <i>Journal of Clinical Virology</i> , 2007, 38, 87-90.	1.6	13
495	Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 440-444.	2.0	13
496	No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8 ⁺ Responses between Long-Term Nonprogressors and Typical Progressors. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1185-1195.	0.5	13
497	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	1.0	13
498	Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.	0.6	13
499	Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1262-1264.	0.5	13
500	Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1015-1022.	1.5	13
501	Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. <i>Cancer</i> , 2018, 124, 1647-1649.	2.0	13
502	Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. <i>European Journal of Epidemiology</i> , 1996, 12, 625-629.	2.5	12
503	Primary lymphoma of the central nervous system and HTLV-I infection. <i>Haematologia</i> , 2001, 31, 365-367.	0.2	12
504	A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. <i>HIV Medicine</i> , 2002, 3, 229-238.	1.0	12

#	ARTICLE	IF	CITATIONS
505	Performance of drug resistance assays in testing HIV-1 non-B subtypes. <i>Clinical Microbiology and Infection</i> , 2003, 9, 323-326.	2.8	12
506	Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. <i>Clinical Microbiology and Infection</i> , 2003, 9, 422-425.	2.8	12
507	Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 739-741.	0.5	12
508	Risks and benefits of antiretroviral therapy in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2005, 42, 290-292.	1.8	12
509	Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. <i>Clinical and Experimental Immunology</i> , 2007, 149, 171-177.	1.1	12
510	Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 398-406.	1.5	12
511	A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008, 22, 911-912.	1.0	12
512	A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 51-58.	0.9	12
513	Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.	1.6	12
514	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173.	1.0	12
515	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	0.6	12
516	Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1027-1032.	2.8	12
517	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015, 71, 63-66.	1.6	12
518	Occult hepatitis B and HIV infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1403-1407.	0.8	12
519	Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. <i>Journal of HIV Therapy</i> , 2009, 14, 13-8.	0.6	12
520	Diabetes Mellitus Associated with Protease Inhibitor Use. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 675-677.	1.3	11
521	Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773.	0.5	11
522	Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4421-4423.	1.8	11

#	ARTICLE	IF	CITATIONS
523	Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. <i>Aids</i> , 2004, 18, 1251-1261.	1.0	11
524	Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2005, 41, 897-900.	2.9	11
525	Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses. <i>Current Molecular Medicine</i> , 2007, 7, 446-458.	0.6	11
526	Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. <i>Antiviral Research</i> , 2010, 88, 152-159.	1.9	11
527	New therapeutic strategies for raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 218-223.	1.3	11
528	Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010, 24, 777-779.	1.0	11
529	New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. <i>Aids</i> , 2011, 25, 1013-1014.	1.0	11
530	Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1043-1045.	0.5	11
531	HIV gag-specific immune response mediated by double negative (CD3 ⁺ CD4 ⁺ CD8 ⁻) T cells in HIV-exposed seronegative individuals. <i>Journal of Medical Virology</i> , 2013, 85, 200-209.	2.5	11
532	Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014, 46, 290-296.	1.5	11
533	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 700-708.	0.6	11
534	Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1119-1130.	1.5	11
535	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543.	1.0	11
536	HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012). <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 11.	0.5	11
537	Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx228.	0.4	11
538	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 45-50.	1.5	11
539	Pyomyositis in patients with HIV infection. <i>Aids</i> , 1993, 7, 1020-1021.	1.0	10
540	Circulating Hepatitis C Virus Genotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 180-181.	0.7	10

#	ARTICLE	IF	CITATIONS
541	Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449.	0.9	10
542	Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. <i>Transfusion Science</i> , 1997, 18, 63-69.	0.6	10
543	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11.	1.7	10
544	Prevalence and Genetic Heterogeneity of the Reverse Transcriptase T69S-S-X Insertion in Pretreated HIV-Infected Patients. <i>Intervirology</i> , 2001, 44, 339-343.	1.2	10
545	Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. <i>Journal of Medical Virology</i> , 2001, 64, 217-222.	2.5	10
546	HIV-1 Subtype J Recombinant Viruses in Spain. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 523-529.	0.5	10
547	Infection with Retroviruses Other Than HIV-1 in Spain: A Retrospective Analysis for HIV-2, HTLV-I, and/or HTLV-II. <i>HIV Clinical Trials</i> , 2002, 3, 397-402.	2.0	10
548	Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. <i>Aids</i> , 2006, 20, 451-453.	1.0	10
549	Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. <i>Drug Metabolism Letters</i> , 2007, 1, 81-84.	0.5	10
550	Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens. <i>HIV Clinical Trials</i> , 2008, 9, 309-313.	2.0	10
551	New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382.	1.3	10
552	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	1.7	10
553	Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013, 58, 391-395.	1.6	10
554	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696.	1.0	10
555	Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035.	0.6	10
556	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057.	0.9	10
557	Molecular Epidemiology and Clinical Features of Human T Cell Lymphotropic Virus Type 1 Infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 856-862.	0.5	10
558	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	1.4	10

#	ARTICLE	IF	CITATIONS
559	Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. <i>AIDS Reviews</i> , 2021, 22, 44-56.	0.5	10
560	Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007, 9, 99-113.	0.5	10
561	Misdiagnosis of HTLV-II infection using HTLV-I screening assays. <i>Aids</i> , 1993, 7, 1395.	1.0	9
562	Significance of HCV RIBA Indeterminate Results in High-Risk Individuals: Assessment by a New Third-Generation RIBA Assay and PCR. <i>Vox Sanguinis</i> , 1994, 66, 148-149.	0.7	9
563	Evidence of HIV-2 Infection in Equatorial Guinea (Central Africa): Partial Genetic Analysis of a B Subtype Virus. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 439-440.	0.5	9
564	Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425.	0.3	9
565	Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?. <i>HIV Clinical Trials</i> , 2002, 3, 463-467.	2.0	9
566	Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. <i>HIV Clinical Trials</i> , 2002, 3, 249-257.	2.0	9
567	New Hopes for HIV and HCV Coinfection in 2004. <i>HIV Clinical Trials</i> , 2004, 5, 232-251.	2.0	9
568	Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. <i>Haemophilia</i> , 2005, 11, 433-437.	1.0	9
569	Variability in the P6 gag domains of HIV-1 involved in viral budding. <i>Aids</i> , 2006, 20, 624-627.	1.0	9
570	Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1411-1413.	1.3	9
571	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008, 5, 86-93.	1.1	9
572	Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385.	0.5	9
573	Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 965-967.	0.5	9
574	Drug resistance testing in hepatitis C therapy. <i>Future Virology</i> , 2012, 7, 309-321.	0.9	9
575	Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. <i>Aids</i> , 2012, 26, 551-557.	1.0	9
576	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	1.3	9

#	ARTICLE	IF	CITATIONS
577	A polymorphism linked to <i>RRAS</i> , <i>SCAF1</i> , <i>IRF3</i> and <i>BCL2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014, 34, 558-566.	1.9	9
578	Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803.	0.6	9
579	AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities. <i>Viruses</i> , 2018, 10, 293.	1.5	9
580	Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains. <i>Emerging Microbes and Infections</i> , 2020, 9, 913-923.	3.0	9
581	Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48.	2.1	9
582	What dual protease inhibitor combination for salvage therapies?. <i>Aids</i> , 1999, 13, 2180.	1.0	9
583	Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. <i>Aids</i> , 2002, 16, 1087-1089.	1.0	9
584	The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. <i>AIDS Reviews</i> , 2015, 17, 212-9.	0.5	9
585	Multifocal splenic abscesses caused by <i>Mycobacterium tuberculosis</i> in HIV-infected drug users. <i>Aids</i> , 1991, 5, 901.	1.0	8
586	Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922.	1.0	8
587	Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 955-957.	0.5	8
588	Higher antiviral activity of antiretroviral regimens including protease inhibitors. <i>Aids</i> , 1999, 13, 998.	1.0	8
589	Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6.	2.5	8
590	Failure of Hepatitis C Therapy in HIV-Infected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype. <i>Journal of Infectious Diseases</i> , 2005, 192, 1245-1248.	1.9	8
591	Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2005, 19, 621-623.	1.0	8
592	Short Communication:Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1078-1082.	0.5	8
593	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008, 22, 311-313.	1.0	8
594	Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV-Infected Patient despite Continuous HCV Replication. <i>Clinical Infectious Diseases</i> , 2009, 48, 1634-1635.	2.9	8

#	ARTICLE	IF	CITATIONS
595	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	1.4	8
596	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740.	2.5	8
597	ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 27-32.	0.9	8
598	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015, 16, 72-80.	2.0	8
599	Gene therapy for HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 319-327.	1.4	8
600	Tenofovir for Hepatitis Delta. <i>Hepatology</i> , 2016, 63, 1395-1396.	3.6	8
601	Hepatitis Delta Enters a New Therapeutic Era. <i>Journal of Infectious Diseases</i> , 2018, 217, 1173-1176.	1.9	8
602	Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1063-1065.	0.8	8
603	HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670.	0.8	8
604	Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz036.	0.4	8
605	HTLV-1 infection and health outcomes. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 407-408.	4.6	8
606	New SARS-CoV-2 Variants Challenge Vaccines Protection. <i>AIDS Reviews</i> , 2021, 23, 57-58.	0.5	8
607	Envisioning a hepatitis delta cure with new antivirals. <i>Future Microbiology</i> , 2021, 16, 927-930.	1.0	8
608	Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000, 14, 2409-2410.	1.0	8
609	HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , 2014, 16, 152-9.	0.5	8
610	Hepatitis A Outbreaks in European Homosexual Men. <i>AIDS Reviews</i> , 2017, 19, 113-114.	0.5	8
611	Evaluation of a New Saliva Collection Device for HIV Antibody Screening Purposes. <i>Vox Sanguinis</i> , 1994, 66, 244-244.	0.7	7
612	Ion-pair reversed-phase and low-molecular-weight aqueous gel permeation high-performance liquid chromatography methods for the determination of amoxicillin oligomers. <i>Chromatographia</i> , 1995, 41, 651-656.	0.7	7

#	ARTICLE	IF	CITATIONS
613	High Rate of Indeterminate Reactivity to HTLV in Western Blot Analysis of Spanish Blood Donors¹. Vox Sanguinis, 1996, 70, 120-121.	0.7	7
614	Sexual Transmission of Two Different HCV Types Causing Acute Hepatitis C. Vox Sanguinis, 1996, 71, 244-245.	0.7	7
615	SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. AIDS Research and Human Retroviruses, 2003, 19, 1079-1082.	0.5	7
616	Long-Term Outcome of HIV-Infected Patients with Multinucleoside-Resistant Genotypes. HIV Clinical Trials, 2003, 4, 372-381.	2.0	7
617	Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B. HIV Clinical Trials, 2005, 6, 103-106.	2.0	7
618	Can the Level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis?. Vaccine Journal, 2006, 13, 160-161.	3.2	7
619	Short Communication: Hospital-Based Surveillance for HTLV-1/2 Infections in Spain. AIDS Research and Human Retroviruses, 2007, 23, 1075-1077.	0.5	7
620	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	0.9	7
621	Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. Infectious Disease Clinics of North America, 2012, 26, 931-948.	1.9	7
622	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. Aids, 2013, 27, 2715-2724.	1.0	7
623	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2015, 16, 179-186.	0.9	7
624	Host and disease factors are associated with cognitive function in European <sc>HIV</sc>-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	1.0	7
625	Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986802.	1.1	7
626	Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611985146.	1.1	7
627	Treatment outcome in dually HIV-1 and HIV-2 coinfecting patients living in Spain. Aids, 2019, 33, 2167-2172.	1.0	7
628	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	1.3	7
629	Hepatitis delta in patients hospitalized in Spain (1997-2018). Aids, 2021, 35, 2311-2318.	1.0	7
630	Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. Aids, 2022, 36, 249-256.	1.0	7

#	ARTICLE	IF	CITATIONS
631	Detection of HTLV-II proviral sequences in HIV-immunosuppressed patients with HTLV indeterminate serological patterns. <i>Journal of Infection</i> , 1998, 36, 243-244.	1.7	6
632	Role of Nonnucleosides in the Development of HAART-Related Lipid Disturbances. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 496-498.	0.9	6
633	Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons. <i>HIV Clinical Trials</i> , 2002, 3, 351-353.	2.0	6
634	How effective is HAART in HCV and HIV coinfection?. <i>Aids</i> , 2004, 18, 2081-2084.	1.0	6
635	Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients. <i>Journal of Clinical Virology</i> , 2005, 32, 338-339.	1.6	6
636	Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. <i>Aids</i> , 2007, 21, 2253-2254.	1.0	6
637	Short Communication:HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+Responses But Has No Impact on Its Functionality. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1197-1201.	0.5	6
638	HIV-1 Infection in Persistently HIV-1-Seronegative Individuals: More Reasons for HIV RNA Screening. <i>Clinical Infectious Diseases</i> , 2008, 46, 785-785.	2.9	6
639	Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158.	1.4	6
640	Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009, 4, 423-430.	0.9	6
641	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410.	1.3	6
642	Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424.	0.5	6
643	Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194.	1.6	6
644	Prevalence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Different Risk Populations in Spain. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1089-1094.	0.5	6
645	Liver fibrosis progression in HIV+HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy. <i>Antiviral Therapy</i> , 2013, 19, 287-292.	0.6	6
646	TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67.	1.6	6
647	High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2016, 21, 489-494.	0.6	6
648	Need to Face Liver Cirrhosis after HCV Cure with Antivirals. <i>EBioMedicine</i> , 2017, 24, 24-25.	2.7	6

#	ARTICLE	IF	CITATIONS
649	Impact of <i>ITPA</i> Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2017, 22, 571-575.	0.6	6
650	Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 610-612.	0.5	6
651	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. <i>PLoS ONE</i> , 2017, 12, e0184329.	1.1	6
652	Unveiling Long COVID-19 Disease. <i>AIDS Reviews</i> , 2021, 22, 227-228.	0.5	6
653	Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2022, 29, 777-784.	1.0	6
654	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	1.0	6
655	Evaluation of a New Fluorescence Immunoassay for CD4+ and CD8+ T Cell Counts in Clinical Samples. <i>Vox Sanguinis</i> , 1994, 67, 86-87.	0.7	5
656	Serial Dilutions on Synthetic Peptide-Based Assays Can Resolve Dual Seroreactivity to HIV-1 and HIV-2. <i>Vox Sanguinis</i> , 1996, 71, 67-68.	0.7	5
657	Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900.	0.5	5
658	Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473.	0.5	5
659	Human T-cell Leukemia/Lymphoma Virus Type II Infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 75-76.	1.3	5
660	Intensification of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 499-506.	0.5	5
661	Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors. <i>HIV Clinical Trials</i> , 2005, 6, 50-61.	2.0	5
662	Host genetics. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 491-500.	1.5	5
663	A New Era for Hepatitis C – New Diagnostics Tools and New Weapons. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 440-441.	1.3	5
664	Very Late HCV Relapse following Triple Therapy for Hepatitis C. <i>Antiviral Therapy</i> , 2014, 19, 723-724.	0.6	5
665	HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2191-2194.	1.3	5
666	PPAR β Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 113-119.	0.9	5

#	ARTICLE	IF	CITATIONS
667	European mitochondrial haplogroups are not associated with hepatitis C virus (<sc>HCV</sc>) treatment response in <sc>HIV</sc>/<sc>HCV</sc>-coinfected patients. HIV Medicine, 2014, 15, 425-430.	1.0	5
668	<i>IL15</i> polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver International, 2016, 36, 1258-1266.	1.9	5
669	Acute hepatitis C virus re-infection in a heterosexual <sc>HIV</sc>-positive partner. Liver International, 2016, 36, 763-763.	1.9	5
670	V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. Aids, 1999, 13, 532.	1.0	5
671	Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. Aids, 2000, 14, 1659-1660.	1.0	5
672	Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización. Medicina Clínica, 2003, 121, 310-315.	0.3	5
673	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.	1.1	5
674	Caution with new oral hepatitis C drugs. AIDS Reviews, 2015, 17, 121-2.	0.5	5
675	Report from the International Conference on Viral Hepatitis - 2017. AIDS Reviews, 2018, 20, 58-70.	0.5	5
676	Hepatitis B Gene Therapy Coming to Age. AIDS Reviews, 2018, 20, 125-127.	0.5	5
677	HTLV-II Infection among Immigrants to Spain. Vox Sanguinis, 1994, 67, 79-80.	0.7	4
678	Idiopathic CD4+ T Lymphocytopenia: A Review and Current Perspective. Transfusion Medicine Reviews, 1994, 8, 223-231.	0.9	4
679	Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome. Aids, 1994, 8, 267.	1.0	4
680	Avoiding false-negative results for HTLV-II using new serological assays. American Journal of Medicine, 1995, 98, 103.	0.6	4
681	Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. Clinical Infectious Diseases, 2002, 34, 1288-1289.	2.9	4
682	Rapid Assessment of Phenotypic Resistance to Protease Inhibitors in Human Immunodeficiency Virus Type 1 Group O. Journal of Clinical Microbiology, 2002, 40, 4313-4316.	1.8	4
683	Transmission of HIV Type 1 through Blood Transfusion from an Antibody-Negative/p24 Antigen-Negative Donor. AIDS Research and Human Retroviruses, 2003, 19, 447-448.	0.5	4
684	Hepatitis B Virus Infection Despite Receiving Lamivudine in One HIV-Infected Person. HIV Clinical Trials, 2003, 4, 77-78.	2.0	4

#	ARTICLE	IF	CITATIONS
685	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004, 18, 689-690.	1.0	4
686	CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147.	1.3	4
687	The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. <i>Immunology</i> , 2011, 134, 305-313.	2.0	4
688	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.	1.3	4
689	High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. <i>HIV Medicine</i> , 2014, 15, n/a-n/a.	1.0	4
690	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.	2.3	4
691	Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs. <i>Virology Journal</i> , 2015, 12, 4.	1.4	4
692	Is HIV still a special population for the treatment of hepatitis C?. <i>Aids</i> , 2016, 30, 2001-2003.	1.0	4
693	Antiretroviral treatment of HIV-2 infection. <i>Future Virology</i> , 2017, 12, 461-472.	0.9	4
694	Keeping alive enterprises while embracing unprecedented COVID-19 restrictions. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612092017.	1.1	4
695	COVID-19 Comes 40 Years After AIDS - Any Lesson?. <i>AIDS Reviews</i> , 2021, 22, 63-77.	0.5	4
696	Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 207.	1.0	4
697	Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. <i>Aids</i> , 2001, 15, 2469-2470.	1.0	4
698	Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. <i>Aids</i> , 2003, 17, 442-444.	1.0	4
699	Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. <i>Aids</i> , 2003, 17, 919-921.	1.0	4
700	Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. <i>AIDS Reviews</i> , 2016, 18, 222-223.	0.5	4
701	HTLV-1 Infection is Rising Up in Spain Whereas HTLV-2 is Vanishing. <i>AIDS Reviews</i> , 2019, 21, 233-235.	0.5	4
702	Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. <i>HIV Clinical Trials</i> , 2002, 3, 249-57.	2.0	4

#	ARTICLE	IF	CITATIONS
703	Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. <i>Hepatology International</i> , 2022, 16, 1161-1169.	1.9	4
704	Treatment of hepatitis delta and <scp>HIV</scp> infection. <i>Liver International</i> , 2023, 43, 108-115.	1.9	4
705	Insufficiencies of the New WHO Western Blot Criteria in the Diagnosis of HIVâ€1 and HIVâ€2 Infections. <i>Vox Sanguinis</i> , 1992, 62, 191-192.	0.7	3
706	Sequence Analysis of the V1/V2 and V3 Domains in an HIV-Seronegative AIDS Patient. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1539-1541.	0.5	3
707	Correlation between Serological and Genetic Methods for Typing Hepatitis C Virus. <i>Vox Sanguinis</i> , 1996, 71, 190-191.	0.7	3
708	CCR5 Genotype and Human Immunodeficiency Virus Typeâ€1 Infection in Perinatally Exposed Infants. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 389-391.	1.3	3
709	Motivo de ingreso hospitalario en pacientes con infecciÃ³n por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. <i>Medicina ClÃ¡nica</i> , 2002, 119, 293-295.	0.3	3
710	Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2003, 37, 460-461.	2.9	3
711	Replacement of Protease Inhibitors by Nevirapine or Efavirenz in Simplification and Rescue Interventions: Which Works Better?. <i>HIV Clinical Trials</i> , 2003, 4, 244-247.	2.0	3
712	Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. <i>Intervirology</i> , 2004, 47, 350-354.	1.2	3
713	<i>Short Communication: </i>Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 389-391.	0.5	3
714	Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user. <i>Aids</i> , 2008, 22, 318.	1.0	3
715	Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. <i>Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ¡nica</i> , 2009, 27, 28-32.	0.3	3
716	The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies. <i>Vaccine</i> , 2009, 27, 2674-2679.	1.7	3
717	Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011, 18, 542-548.	1.0	3
718	Cardiovascular Disease Risk in HIV Infection and Endothelial Progenitor Cells. <i>Journal of Infectious Diseases</i> , 2012, 206, 1479-1480.	1.9	3
719	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013, 12, 269-275.	0.3	3
720	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	1.7	3

#	ARTICLE	IF	CITATIONS
721	The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19 Outbreak. <i>AIDS Reviews</i> , 2020, 22, 123-124.	0.5	3
722	Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir. <i>Aids</i> , 1997, 11, 1896-1897.	1.0	3
723	Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020, 22, 168-172.	0.5	3
724	Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612098212.	1.1	3
725	RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola. <i>AIDS Reviews</i> , 2014, 16, 246-7.	0.5	3
726	Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis. <i>AIDS Reviews</i> , 2017, 19, 54-55.	0.5	3
727	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. <i>HIV Medicine</i> , 2022, 23, 639-649.	1.0	3
728	Synthetic Peptide Immunoassay for Diagnosis of HIV 2 Infection. <i>Vox Sanguinis</i> , 1989, 57, 222-222.	0.7	2
729	Significance of Positive Polymerase Chain Reaction Results in HIV Seronegative Individuals. <i>Vox Sanguinis</i> , 1992, 63, 287-288.	0.7	2
730	Prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Aids</i> , 1993, 7, 1133.	1.0	2
731	Circulating HIV Serotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 236-237.	0.7	2
732	Sequence Note: Genetic Analysis of Human Immunodeficiency Virus Type 2 Strains from Spain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 91-94.	0.5	2
733	Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. <i>Medicina Clínica</i> , 2000, 115, 118.	0.3	2
734	Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations. <i>Journal of Clinical Microbiology</i> , 2004, 42, 862-866.	1.8	2
735	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842.	0.9	2
736	Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. <i>Aids</i> , 2007, 21, 652-653.	1.0	2
737	Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374.	1.0	2
738	648 DIFFERENCES IN ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA 2A AND 2B IN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2009, 50, S238-S239.	1.8	2

#	ARTICLE	IF	CITATIONS
739	Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 866-871.	1.0	2
740	Short Communication: RNASEL Alleles and Susceptibility to Infection by Human Retroviruses and Hepatitis Viruses. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1259-1261.	0.5	2
741	Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. <i>AIDS Research and Therapy</i> , 2012, 9, 23.	0.7	2
742	Long-Term Use of Atazanavir in the Treatment of HIV-Infected patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S5764.	0.4	2
743	No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. <i>Antiviral Research</i> , 2012, 95, 67-71.	1.9	2
744	Is Ribavirin Teratogenic in Humans? No Evidence So Far. <i>Drug Safety</i> , 2017, 40, 1163-1165.	1.4	2
745	JÃ©rÃ©me Lejeune passed away 25 years ago. <i>Hereditas</i> , 2019, 156, 18.	0.5	2
746	Tough requirements for new antiretroviral drugs. <i>Lancet HIV</i> , 2020, 7, e150-e151.	2.1	2
747	Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections. <i>AIDS Reviews</i> , 2020, 22, 124-127.	0.5	2
748	Use of antibiotics in respiratory viral infections. <i>Internal and Emergency Medicine</i> , 2022, 17, 1569-1570.	1.0	2
749	HIV-2 Infection in high-risk individuals in Spain. <i>Transfusion Science</i> , 1993, 14, 167-172.	0.6	1
750	Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated <i>Mycobacterium avium</i> complex infection receiving clofazimine. <i>Aids</i> , 1993, 7, 894.	1.0	1
751	Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. <i>Journal of Infection</i> , 1997, 35, 202-203.	1.7	1
752	Is there a role for indinavir twice-daily in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2000, 6, 152-154.	2.8	1
753	Response to Drs. Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3442.	0.2	1
754	¿Se deberÃ­a recomendar el cribado de la infecci3n por el virus linfotrÃ­pico humano de cÃ©lulas T de tipo 1 en las mujeres embarazadas?. <i>Progresos En Obstetricia Y Ginecologia</i> , 2006, 49, 523-525.	0.0	1
755	Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. <i>Infectious Disorders - Drug Targets</i> , 2006, 6, 57-68.	0.4	1
756	Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 482-488.	1.5	1

#	ARTICLE	IF	CITATIONS
757	Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. HIV Clinical Trials, 2008, 9, 348-365.	2.0	1
758	Differences in Lopinavir Plasma Concentrations Comparing Kaletra; Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities. Drug Metabolism Letters, 2009, 3, 67-69.	0.5	1
759	Resistance data in the ARTEN trial. Antiviral Therapy, 2011, 16, 1135-1136.	0.6	1
760	HCV and HIV Coinfection. Current Hepatitis Reports, 2011, 10, 52-61.	0.3	1
761	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology and Hepatology, 2016, 28, 923-926.	0.8	1
762	SOLAR-2: the sun also rises for cirrhotics. Lancet Infectious Diseases, The, 2016, 16, 624-625.	4.6	1
763	Hepatitis Delta Estimates in the United States Revisited. Clinical Infectious Diseases, 2019, 69, 1833-1834.	2.9	1
764	Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation. Transplantation Proceedings, 2021, 53, 743-745.	0.3	1
765	Situación epidemiológica actual de la infección por VIH-2 y HTLV-1 en España. Medicina Clínica, 2021, 156, 290-296.	0.3	1
766	Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication, 2018, 4, 196-207.	0.3	1
767	Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. AIDS Reviews, 2016, 18, 81-8.	0.5	1
768	A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy. AIDS Reviews, 2017, 19, 113-114.	0.5	1
769	Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. Journal of Infectious Diseases, 1988, 158, 894-894.	1.9	0
770	HIV in Spanish Drug Abusers. Vox Sanguinis, 1989, 57, 157-157.	0.7	0
771	Non-Parenteral Transmission of Hepatitis C Virus. International Journal of STD and AIDS, 1991, 2, 449-450.	0.5	0
772	Human Herpesvirus 6 in Spain: Seroprevalence in Blood Donors and Patients with Lymphoproliferative Disorders or HIV Infection. Vox Sanguinis, 1991, 60, 63-64.	0.7	0
773	Hepatitis C Virus Genotypes 1a and 1b Mixed Infections. Vox Sanguinis, 1997, 72, 64-64.	0.7	0
774	Association Between Submaximal Suppression of HIV Replication and Use of Drug Combinations Without Protease Inhibitors. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 604-605.	1.3	0

#	ARTICLE	IF	CITATIONS
775	Tolerability of Abacavir in the clinical setting. <i>Clinical Microbiology and Infection</i> , 2000, 6, 621-622.	2.8	0
776	Response to Drs. Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3442.	0.2	0
777	Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in HIV-infected patients. <i>Journal of Hepatology</i> , 2002, 36, 107.	1.8	0
778	Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 108.	1.8	0
779	Reply to Bruno et al.. <i>Aids</i> , 2004, 18, 2102-2103.	1.0	0
780	Phage Display Selection of HIV Specific Conserved Mimotopes With IgG from Long-term Non-progressors. <i>Retrovirology</i> , 2005, 2, P29.	0.9	0
781	Standard of Care for HCV/HIV-Coinfected Patients. <i>Journal of Chemotherapy</i> , 2006, 18, 21-26.	0.7	0
782	Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption. <i>Retrovirology</i> , 2010, 7, .	0.9	0
783	Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients. <i>Retrovirology</i> , 2010, 7, .	0.9	0
784	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists--authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2057-2058.	1.3	0
785	HIV and Liver Disease. <i>Seminars in Liver Disease</i> , 2012, 32, 101-102.	1.8	0
786	B3â€fIdentification of Neutralizing Antibodies and Their Epitopes From HIV Controllers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 74.	0.9	0
787	Author's response: expert reviews: who are they for?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1217-1218.	0.9	0
788	P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPY. <i>Journal of Hepatology</i> , 2014, 60, S321.	1.8	0
789	Corrigendum. <i>HIV Clinical Trials</i> , 2015, 16, 236-238.	2.0	0
790	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). <i>Journal of Virus Eradication</i> , 2016, 2, 187-192.	0.3	0
791	Delta hepatitis: new approaches to therapy. <i>Future Virology</i> , 2016, 11, 197-205.	0.9	0
792	Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 226-231.	0.5	0

#	ARTICLE	IF	CITATIONS
793	Human T-Lymphotropic Virus Infection in Hepatitis C Virus Antibody Positive Patients in Spain. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1013-1017.	0.5	0
794	Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. <i>Medicina Clínica (English)</i> 10 Tf 50	0.1	0
795	Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 578.	0.1	0
796	COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. <i>AIDS Reviews</i> , 2021, 23, 115-116.	0.5	0
797	Consideraciones sobre la infección por HTLV-1 en España. <i>Medicina Clínica</i> , 2021, 156, 578.	0.3	0
798	The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 242-244.	1.0	0
799	A Key Action Plan for EDUCATION in a Global Crisis. <i>Lecture Notes in Educational Technology</i> , 2021, , 263-272.	0.5	0
800	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, France. <i>Journal of Virus Eradication</i> , 2016, 2, 187-92.	0.3	0
801	Another patient has cured HIV infection. <i>AIDS Reviews</i> , 2022, 23, 226-227.	0.5	0
802	Non-Human Cancers in AIDS Patients. <i>AIDS Reviews</i> , 2015, 17, 238-9.	0.5	0
803	Acute Viral Hepatitis in Men Having Sex with Men. <i>AIDS Reviews</i> , 2020, 22, 168-172.	0.5	0
804	A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990s. <i>AIDS Reviews</i> , 2022, 24, 50.	0.5	0
805	The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America. <i>Journal of Clinical Virology</i> , 2022, 153, 105195.	1.6	0